You are here
San Francisco, CA
Ablexis' AlivaMab™ Mouse technology, a world-class transgenic mouse platform, is being developed to provide the foundation for the efficient discovery and development of the next wave of human therapeutic antibodies to treat human diseases. Ablexis will commercialize the AlivaMab™ Mouse platform through creative partnering strategies.
New York, NY
Accelerator New York is a leading life science investment vehicle supporting emerging biotechnology research. Accelerator will infuse strategic venture capital, entrepreneurial leadership, and critical product development capabilities into the New York City life science cluster. Accelerator NY is located at the Alexandria Center for Life Science in the heart of Manhattan’s East Side Medical Corridor.
Aquinox is developing novel small molecule therapeutics for the treatment of cancer and inflammatory disease. Aquinox's scientific founders discovered a unique biochemical enzyme called SH2-containing inositol 5'-phosphatase (known as SHIP), which can be harnessed in the treatment of disorders such as multiple myeloma, leukemia, lymphoma, inflammation, allergy and autoimmune diseases. The lead candidate, AQX-1125, is being tested in Phase 2a studies of airway inflammation.
Autifony is developing novel medicines to treat hearing disorders. The company was spun-out from GSK in 2011. Phase 1 studies are underway with the company’s lead program, AUT00063, which is a novel pharmaceutical that targets auditory processing in the brain.
Palo Alto, CA
Aviir is developing cutting-edge, convenient molecular diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology applies a deep understanding of disease marker proteins and advanced biostatistics to build prognostic profiles for atherosclerosis and is also aiming to develop a prognostic test for insulin resistance in the future.
Biodesy is a life science instrumentation company that has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. The technology can be used to measure functional activation in a protein upon binding drugs or ligands, in real time and without the need for a crystal structure.
La Jolla, CA
Celladon is focused on developing molecular therapies for cardiovascular diseases. Their first product is designed to target the key enzyme deficiency in advanced heart failure which regulates calcium cycling and contractility in heart muscle cells.
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents. Clovis intends to target development programs at specific subsets of cancer populations, and will simultaneously develop diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use.
Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising assets with well understood biology and proof-of-concept data in animal models from academia, industry and other sources. Data generated during a rigorous de-risking process will enable formation of stand alone companies and strategic partnerships.
South San Francisco, CA
CytomX Therapeutics is developing Probody™ therapeutics for the treatment of cancer. Probodies are masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, unlocking new therapeutic targets. The Company is initially focused in the discovery and development of new immunotherapy and antibody drug conjugate therapies to treat major unmet medical needs in oncology.
La Jolla, CA
Epic Sciences is focused on developing novel diagnostics to improve and personalize the treatment and management of cancer. Epic was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs).
Flexion Therapeutics discovers and develops innovative therapeutics for musculo-skeletal disease. The company is currently advancing a portfolio of best-in-class candidates that have the potential to treat mild, moderate and severe forms of osteoarthritis. The independent company was founded by Mike Clayman and Neil Bodick, both deeply knowledgeable drug developers, who previously created Eli Lilly's Chorus division.
G-Con designs and manufactures “PODs”, portable, self-contained cGMP facility modules that offer a cost-effective and flexible alternative to large, highly capitalized pharmaceutical manufacturing facilities with fixed equipment and limited flexibility.
HD Biosciences (HDB) is a Shanghai China based clinical research organization (CRO) that provides drug discovery contract research services, with an emphasis on high value biology screening. The company has developed comprehensive technology platforms and expertise around drug discovery assays, assay development, high throughput drug screening, and hit-to-lead biology. HD Biosciences customers include Pfizer and several other large pharmaceutical companies.
M2S is a pioneer and leader in imaging and data management technology. They were the first to develop and market 3-D imaging technology to vascular surgeons. Their Preview product is still the market leader in this field. In 2006, the company expanded into providing core lab services for clinical trials and customized data registries for physicians, hospitals, medical centers, and clinical researchers.
Utrecht, The Netherlands
Merus is building a pipeline of innovative human bispecific antibodies (Biclonics™) and single cell-derived combinations of antibodies (Oligoclonics®) for cancer therapy. Using a common antibody light chain (cLC) and CH3 dimerization technology, these full length IgG antibodies can be robustly produced at high yields from a clonal manufacturing cell line using standard approaches. Novel fully human cLC antibodies are produced following immunization in Merus' transgenic MeMo mouse.
Mersana is developing a portfolio of next-generation antibody-drug conjugates (ADCs) with superior properties not found with other ADC technologies.
MIRNA is harnessing the power of tumor suppressor microRNAs to kill cancer cells by regaining control over multiple oncogenic pathways. Tumor suppressor miRNAs represent a new paradigm in cancer therapy. MIRNA's pipeline has broad utility in the treatment of solid and hematologic cancers.
MISSION is a drug discovery company focused on elucidating and targeting the ubiquitin pathway to treat cancer and other diseases. The company is developing small molecule drugs that target deubiquitinylating enzymes (DUBs) involved in the DNA damage response (DDR), which tumor cells rely upon for driving cell growth.
Ann Arbor, MI
NeuMoDx is developing a next generation testing platform for the in vitro molecular diagnostic (MDx) market. The product vision is to create a walk-away bench-top system that combines sensitivity, high speed (time to first result and throughput), low cost, and random access, in an “open” architecture that can support both IVDs and Lab Developed Tests (LDTs).
Focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses, Neuronetics is the first company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. Neuronetics is the leader in the development of NeuroStar TMS Therapy (transcranial magnetic stimulation), a non-invasive form of neuromodulation.
NexImmune is developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIMTM) technology. The AIM technology has been designed to orchestrate specific immune system responses in a highly controllable and reproducible way independent of the healthiness or abundance of the patient’s natural antigen presenting cells (APC). NexImmune is applying the AIM technology to the development of immuno-therapies for a variety of cancers and other diseases.
Nimbus harnesses the power of computational chemistry to design breakthroughs for the treatment of substantial and underserved human diseases. The company’s focus on metabolic diseases, cancer and immune-inflammatory disorders is driven by its selection of well validated targets that have proven intractable to the approaches taken by others in the pharmaceutical and biotechnology industry. Using its unique approach and technological capabilities, Nimbus is rapidly progressing highly selective and potent small molecules through discovery and development. The company’s advanced programs include ACC, IRAK4, and Tyk2.
South San Francisco, CA
Nodality, Inc. is an emerging biotechnology company focused on patient-specific classification of disease. Nodality's technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The technology can address many aspects of drug development with a primary focus on acute myeloblastic leukemia (AML) and chronic lymphocytic leukemia (CLL).
Therapeutic oncology device that delivers Tumor Treating Fields (TTFields) to tumor sites through the skin. The TTfields are low intensity, alternating electric fields that cause physical disruption of dividing (cancerous) cells, but leave normal cells largely unaffected. The company's lead program in brain cancer (GBM) is has received US regulatory approval. Additional studies are also planned in other major cancer indications.
Quartet is an early-stage biopharmaceutical company developing drugs against a novel pain target, Tetrahydrobiopterin (BH4), an essential co-factor in the production of certain neurotransmitters.
Rhythm is a biopharmaceutical company developing peptide therapeutics that address unmet needs in metabolic diseases: RM-493, a small-peptide melanocortin-4 receptor (MC4R) agonist, for the treatment of obesity and diabetes; and RM-131, a small-peptide ghrelin agonist, for the treatment of diabetic gastroparesis and other gastrointestinal functional disorders.
TetraLogic is a biopharmaceutical company developing novel, targeted drugs to treat cancer. The company's Smac-mimetic candidates regulate the apoptosis (programmed cell death) pathway by unblocking the pathway to kill cancer cells.
Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved. The first spin-out company from Cydan Development, Inc., an orphan-drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, Vtesse is working collaboratively with the NIH to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs.
Ziarco is a clinical stage biotechnology company developing innovative therapeutics targeting inflammatory skin diseases. The company’s lead compounds are ZPL-389, an oral histamine H4 receptor antagonist entering Phase 2 studies for atopic dermatitis and ZPL-521, a cPLA-2 inhibitor being advanced for psoriasis.
Former Portfolio Companies
Aureon Laboratories Out of business
Aureon uses systems pathology to develop predictive clinical tests for cancer care, as well as to enable bio-pharmaceutical research and development. Their technology predicts individual clinical outcomes by interrogating and analyzing tissue, to provide the first comprehensive and fully integrated view of the disease process — a systems pathology view. In 2008, Aureon successfully launched their Px+ prostate biopsy test, which has already seen very rapid uptake in the market.
Avid Radiopharmaceuticals Acquired by Eli Lilly
Avid Radiopharmaceuticals, Inc. is a product-focused molecular imaging company that is a pioneer in developing radiopharmaceuticals for imaging disease pathology. The company's beta-amyloid imaging agent for Alzheimer's disease is in Phase III development. The Avid team is also developing novel agents targeted to image pathology in dementia with Lewy bodies, Parkinson's disease, and has recently started a research project in diabetes mellitus.
DVS Sciences Inc. is an analytical equipment and reagents development company that produces and markets the CyTOF® , a high throughput mass cytometer for individual cell analysis based on a novel elemental mass-spectrometry detection technology, and the MAXPAR® system of novel reagents related to massively multi-parametric assays.
Entelos Restart following bankruptcy
Foster City, CA
Entelos develops computer-based disease-simulation models, called PhysioLabs, that enable in-silico drug discovery and development. Each PhysioLab platform provides a framework for integrating data (e.g., genomic, proteomic, physiologic, environmental) in the context of a disease or therapeutic area, focusing on understanding and determining clinical responses to potential treatment. Using a PhysioLab platform, scientists create virtual patients and simulate experiments and clinical trials in silico that could take months or years to do in the laboratory or clinic.
Evolution Benefits Acquired by Genstar Capital
Evolution Benefits (EB) offers innovative, integrated products for the employee benefits market. Their Benny™ prepaid benefits card acts as a comprehensive tool for managing the front and back-end functions involved in executing employee benefit programs, including flexible spending accounts, health reimbursement accounts, health savings accounts, and qualified transportation accounts. EB's products make benefits programs easier for consumers to use, while at the same time reduce administrative burden to benefit managers. Note: Acquired by Genstar Capital
Redwood City, CA
Genomic Health is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. In early 2004, they launched their first test under the brand name Oncotype DX® for early stage breast cancer patients. Note: IPO in 2005
HandyLab Acquired by Becton Dickinson
Ann Arbor, MI
HandyLab develops and manufactures small, low-cost nucleic acid and protein-based analysis systems based on its patented and proprietary microfluidic, miniaturized real time PCR, and nucleic acid extraction technologies. The company's lead product, Jaguar, combines rapid nucleic acid sample preparation with microfluidic PCR for nucleic acid detection. Note: Acquired by Becton Dickinson
NeuroTherapeutics Pharma Out of business
NeuroTherapeutics Pharma, Inc. (NTP) is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system hyper-excitability. The company is working with novel mechanisms that will generate first-in-class therapeutics, thereby changing the standard of care for patients suffering from epilepsy, neuropathic and acute pain, and other disorders of the nervous system.
superDimension Acquired by Covidien
superDimension has developed the inReachT system in answer to one of the most critical needs in the field of pulmonology: minimally invasive access to peripheral lung locations. The inReachT system enables accurate and minimally invasive navigation anywhere in the lungs in real time and on a 3D CT roadmap, increasing both the success rate and applicability of diagnostic bronchoscopy.
Supplyscape Merged with Tracelink
Provider of pharmaceutical supply chain security solutions to pharmaceutical companies and their trading partners seeking to enhance product integrity and supply chain efficiency. The company has developed technology to track and store the movement of drugs throughout the pharmaceutical supply chain using radio frequency identification to protect the drug supply from counterfeiters. Note: Company acquired